Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study.

Turkbey B, Czarniecki M, Shih JH, Harmon SA, Agarwal PK, Apolo AB, Citrin DE, Gulley JL, Harisinghani M, Madan RA, Metwalli AR, Paquette E, Pinto PA, Rais-Bahrami S, Rowe LS, Wood BJ, Jacobs PM, Lindenberg L, Dahut W, Choyke PL.

AJR Am J Roentgenol. 2019 Oct 15:1-9. doi: 10.2214/AJR.19.21264. [Epub ahead of print]

PMID:
31613660
2.

12-Lipoxygenase is a Critical Mediator of Type II Pneumocyte Senescence, Macrophage Polarization and Pulmonary Fibrosis after Irradiation.

Chung EJ, Reedy JL, Kwon S, Patil S, Valle L, White AO, Citrin DE.

Radiat Res. 2019 Aug;192(4):367-379. doi: 10.1667/RR15356.1. Epub 2019 Aug 2.

PMID:
31373871
3.

Cellular senescence and radiation-induced pulmonary fibrosis.

He Y, Thummuri D, Zheng G, Okunieff P, Citrin DE, Vujaskovic Z, Zhou D.

Transl Res. 2019 Jul;209:14-21. doi: 10.1016/j.trsl.2019.03.006. Epub 2019 Mar 27. Review.

PMID:
30981698
4.

Long-term Tumor Adaptation after Radiotherapy: Therapeutic Implications for Targeting Integrins in Prostate Cancer.

Eke I, Makinde AY, Aryankalayil MJ, Reedy JL, Citrin DE, Chopra S, Ahmed MM, Coleman CN.

Mol Cancer Res. 2018 Dec;16(12):1855-1864. doi: 10.1158/1541-7786.MCR-18-0232. Epub 2018 Jul 24.

PMID:
30042176
5.

A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer.

Harmon SA, Bergvall E, Mena E, Shih JH, Adler S, McKinney Y, Mehralivand S, Citrin DE, Couvillon A, Madan RA, Gulley JL, Mease RC, Jacobs PM, Pomper MG, Turkbey B, Choyke PL, Lindenberg ML.

J Nucl Med. 2018 Nov;59(11):1665-1671. doi: 10.2967/jnumed.117.207373. Epub 2018 Mar 30.

6.

Hyperpolarized [1-13C]-Pyruvate Magnetic Resonance Spectroscopic Imaging of Prostate Cancer In Vivo Predicts Efficacy of Targeting the Warburg Effect.

Scroggins BT, Matsuo M, White AO, Saito K, Munasinghe JP, Sourbier C, Yamamoto K, Diaz V, Takakusagi Y, Ichikawa K, Mitchell JB, Krishna MC, Citrin DE.

Clin Cancer Res. 2018 Jul 1;24(13):3137-3148. doi: 10.1158/1078-0432.CCR-17-1957. Epub 2018 Mar 29.

7.

Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers.

Sourbier C, Liao PJ, Ricketts CJ, Wei D, Yang Y, Baranes SM, Gibbs BK, Ohanjanian L, Spencer Krane L, Scroggins BT, Keith Killian J, Wei MH, Kijima T, Meltzer PS, Citrin DE, Neckers L, Vocke CD, Marston Linehan W.

Oncotarget. 2018 Jan 10;9(12):10723-10733. doi: 10.18632/oncotarget.24112. eCollection 2018 Feb 13.

8.

PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.

Liu Q, Gheorghiu L, Drumm M, Clayman R, Eidelman A, Wszolek MF, Olumi A, Feldman A, Wang M, Marcar L, Citrin DE, Wu CL, Benes CH, Efstathiou JA, Willers H.

Oncogene. 2018 May;37(21):2793-2805. doi: 10.1038/s41388-018-0130-6. Epub 2018 Mar 7.

9.

Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting of biochemical recurrence after low dose rate brachytherapy.

Valle LF, Greer MD, Shih JH, Barrett T, Law YM, Rosenkrantz AB, Shebel H, Muthigi A, Su D, Merino MJ, Wood BJ, Pinto PA, Krauze AV, Kaushal A, Choyke PL, Türkbey B, Citrin DE.

Diagn Interv Radiol. 2018 Jan-Feb;24(1):46-53. doi: 10.5152/dir.2018.17285.

10.

Recent Developments in Radiotherapy.

Citrin DE.

N Engl J Med. 2017 Nov 30;377(22):2200-2201. doi: 10.1056/NEJMc1713349. No abstract available.

PMID:
29171815
11.

Mithramycin A Enhances Tumor Sensitivity to Mitotic Catastrophe Resulting From DNA Damage.

Scroggins BT, Burkeen J, White AO, Chung EJ, Wei D, Chung SI, Valle LF, Patil SS, McKay-Corkum G, Hudak KE, Linehan WM, Citrin DE.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):344-352. doi: 10.1016/j.ijrobp.2017.09.049. Epub 2017 Oct 12.

12.

Recent Developments in Radiotherapy.

Citrin DE.

N Engl J Med. 2017 Sep 14;377(11):1065-1075. doi: 10.1056/NEJMra1608986. Review. No abstract available.

PMID:
28902591
13.

Mechanisms of Normal Tissue Injury From Irradiation.

Citrin DE, Mitchell JB.

Semin Radiat Oncol. 2017 Oct;27(4):316-324. doi: 10.1016/j.semradonc.2017.04.001. Review.

14.

Introduction.

Citrin DE.

Semin Radiat Oncol. 2017 Oct;27(4):299. doi: 10.1016/j.semradonc.2017.05.001. No abstract available.

15.

Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016.

Citrin DE, Prasanna PGS, Walker AJ, Freeman ML, Eke I, Barcellos-Hoff MH, Arankalayil MJ, Cohen EP, Wilkins RC, Ahmed MM, Anscher MS, Movsas B, Buchsbaum JC, Mendonca MS, Wynn TA, Coleman CN.

Radiat Res. 2017 Jul;188(1):1-20. doi: 10.1667/RR14784.1. Epub 2017 May 10.

16.

Inhibition of Bcl-2/xl With ABT-263 Selectively Kills Senescent Type II Pneumocytes and Reverses Persistent Pulmonary Fibrosis Induced by Ionizing Radiation in Mice.

Pan J, Li D, Xu Y, Zhang J, Wang Y, Chen M, Lin S, Huang L, Chung EJ, Citrin DE, Wang Y, Hauer-Jensen M, Zhou D, Meng A.

Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):353-361. doi: 10.1016/j.ijrobp.2017.02.216. Epub 2017 Mar 4.

PMID:
28479002
17.

Effect of Prostate Magnetic Resonance Imaging/Ultrasound Fusion-guided Biopsy on Radiation Treatment Recommendations.

Reed A, Valle LF, Shankavaram U, Krauze A, Kaushal A, Schott E, Cooley-Zgela T, Wood B, Pinto P, Choyke P, Turkbey B, Citrin DE.

Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):947-951. doi: 10.1016/j.ijrobp.2016.12.016. Epub 2016 Dec 18.

18.

IL-13 is a therapeutic target in radiation lung injury.

Chung SI, Horton JA, Ramalingam TR, White AO, Chung EJ, Hudak KE, Scroggins BT, Arron JR, Wynn TA, Citrin DE.

Sci Rep. 2016 Dec 22;6:39714. doi: 10.1038/srep39714.

19.

Mammalian Target of Rapamycin Inhibition With Rapamycin Mitigates Radiation-Induced Pulmonary Fibrosis in a Murine Model.

Chung EJ, Sowers A, Thetford A, McKay-Corkum G, Chung SI, Mitchell JB, Citrin DE.

Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):857-866. doi: 10.1016/j.ijrobp.2016.07.026. Epub 2016 Jul 28.

20.

Short-Term Screening Assays for the Identification of Therapeutics for Cancer.

Citrin DE.

Cancer Res. 2016 Jun 15;76(12):3443-5. doi: 10.1158/0008-5472.CAN-16-1299. No abstract available.

21.

Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.

Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, Zlott DA, Yang JC, Sherry RM, Kammula US, Klebanoff CA, Hughes MS, Restifo NP, Langhan MM, Shelton TE, Lu L, Kwong ML, Ilyas S, Klemen ND, Payabyab EC, Morton KE, Toomey MA, Steinberg SM, White DE, Rosenberg SA.

J Clin Oncol. 2016 Jul 10;34(20):2389-97. doi: 10.1200/JCO.2016.66.7220. Epub 2016 May 23.

22.

Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo.

Simonetti FR, Sobolewski MD, Fyne E, Shao W, Spindler J, Hattori J, Anderson EM, Watters SA, Hill S, Wu X, Wells D, Su L, Luke BT, Halvas EK, Besson G, Penrose KJ, Yang Z, Kwan RW, Van Waes C, Uldrick T, Citrin DE, Kovacs J, Polis MA, Rehm CA, Gorelick R, Piatak M, Keele BF, Kearney MF, Coffin JM, Hughes SH, Mellors JW, Maldarelli F.

Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1883-8. doi: 10.1073/pnas.1522675113. Epub 2016 Feb 8.

23.

Trimodality therapy in bladder cancer: who, what, and when?

Premo C, Apolo AB, Agarwal PK, Citrin DE.

Urol Clin North Am. 2015 May;42(2):169-80, vii. doi: 10.1016/j.ucl.2015.02.002. Review.

24.

Altering the response to radiation: sensitizers and protectors.

Citrin DE, Mitchell JB.

Semin Oncol. 2014 Dec;41(6):848-59. doi: 10.1053/j.seminoncol.2014.09.013. Epub 2014 Oct 7. Review.

25.

Multimodal management of muscle-invasive bladder cancer.

Park JC, Citrin DE, Agarwal PK, Apolo AB.

Curr Probl Cancer. 2014 May-Jun;38(3):80-108. doi: 10.1016/j.currproblcancer.2014.06.001. Epub 2014 Jun 23. Review. No abstract available.

26.

Mass spectrometry in cancer biomarker research: a case for immunodepletion of abundant blood-derived proteins from clinical tissue specimens.

Prieto DA, Johann DJ Jr, Wei BR, Ye X, Chan KC, Nissley DV, Simpson RM, Citrin DE, Mackall CL, Linehan WM, Blonder J.

Biomark Med. 2014;8(2):269-86. doi: 10.2217/bmm.13.101.

27.

Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation.

Tseng J, Citrin DE, Waldman M, White DE, Rosenberg SA, Yang JC.

Cancer. 2014 May 1;120(9):1426-32. doi: 10.1002/cncr.28547. Epub 2014 Jan 28.

28.

Peptidases released by necrotic cells control CD8+ T cell cross-priming.

Gamrekelashvili J, Kapanadze T, Han M, Wissing J, Ma C, Jaensch L, Manns MP, Armstrong T, Jaffee E, White AO, Citrin DE, Korangy F, Greten TF.

J Clin Invest. 2013 Nov;123(11):4755-68.

29.

Role of type II pneumocyte senescence in radiation-induced lung fibrosis.

Citrin DE, Shankavaram U, Horton JA, Shield W 3rd, Zhao S, Asano H, White A, Sowers A, Thetford A, Chung EJ.

J Natl Cancer Inst. 2013 Oct 2;105(19):1474-84. doi: 10.1093/jnci/djt212. Epub 2013 Sep 19.

30.

Mesenchymal stem cells inhibit cutaneous radiation-induced fibrosis by suppressing chronic inflammation.

Horton JA, Hudak KE, Chung EJ, White AO, Scroggins BT, Burkeen JF, Citrin DE.

Stem Cells. 2013 Oct;31(10):2231-41. doi: 10.1002/stem.1483.

31.

MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands.

Chung EJ, Urick ME, Kurshan N, Shield W 3rd, Asano H, Smith PD, Scroggins BS, Burkeen J, Citrin DE.

Int J Oncol. 2013 Jun;42(6):2028-36. doi: 10.3892/ijo.2013.1890. Epub 2013 Apr 10.

32.

Early responses to adenoviral-mediated transfer of the aquaporin-1 cDNA for radiation-induced salivary hypofunction.

Baum BJ, Alevizos I, Zheng C, Cotrim AP, Liu S, McCullagh L, Goldsmith CM, Burbelo PD, Citrin DE, Mitchell JB, Nottingham LK, Rudy SF, Van Waes C, Whatley MA, Brahim JS, Chiorini JA, Danielides S, Turner RJ, Patronas NJ, Chen CC, Nikolov NP, Illei GG.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19403-7. doi: 10.1073/pnas.1210662109. Epub 2012 Nov 5.

33.

Inhibition of radiation-induced skin fibrosis with imatinib.

Horton JA, Chung EJ, Hudak KE, Sowers A, Thetford A, White AO, Mitchell JB, Citrin DE.

Int J Radiat Biol. 2013 Mar;89(3):162-70. doi: 10.3109/09553002.2013.741281. Epub 2012 Nov 19.

PMID:
23083077
34.

Determination of cytokine protein levels in oral secretions in patients undergoing radiotherapy for head and neck malignancies.

Citrin DE, Hitchcock YJ, Chung EJ, Frandsen J, Urick ME, Shield W, Gaffney D.

Radiat Oncol. 2012 Apr 26;7:64. doi: 10.1186/1748-717X-7-64.

35.

Localization of sclerotic-type chronic graft-vs-host disease to sites of skin injury: potential insight into the mechanism of isomorphic and isotopic responses.

Martires KJ, Baird K, Citrin DE, Hakim FT, Pavletic SZ, Cowen EW.

Arch Dermatol. 2011 Sep;147(9):1081-6. doi: 10.1001/archdermatol.2011.226.

PMID:
21931046
36.

Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition.

Urick ME, Chung EJ, Shield WP 3rd, Gerber N, White A, Sowers A, Thetford A, Camphausen K, Mitchell J, Citrin DE.

Clin Cancer Res. 2011 Aug 1;17(15):5038-47. doi: 10.1158/1078-0432.CCR-11-0358. Epub 2011 Jun 20.

37.

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.

Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME.

Clin Cancer Res. 2011 Jul 1;17(13):4550-7. doi: 10.1158/1078-0432.CCR-11-0116. Epub 2011 Apr 15.

38.

Surgical management of melanoma brain metastases in patients treated with immunotherapy.

Lonser RR, Song DK, Klapper J, Hagan M, Auh S, Kerr PB, Citrin DE, Heiss JD, Camphausen K, Rosenberg SA.

J Neurosurg. 2011 Jul;115(1):30-6. doi: 10.3171/2011.3.JNS091107. Epub 2011 Apr 8.

39.

CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.

Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE, Restifo NP, Wunderlich JR, Prieto PA, Hong JJ, Langan RC, Zlott DA, Morton KE, White DE, Laurencot CM, Rosenberg SA.

Clin Cancer Res. 2010 Dec 15;16(24):6122-31. doi: 10.1158/1078-0432.CCR-10-1297. Epub 2010 Jul 28.

40.

Evaluation of the fullerene compound DF-1 as a radiation protector.

Brown AP, Chung EJ, Urick ME, Shield WP 3rd, Sowers AL, Thetford A, Shankavaram UT, Mitchell JB, Citrin DE.

Radiat Oncol. 2010 May 11;5:34. doi: 10.1186/1748-717X-5-34.

41.

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA.

J Clin Oncol. 2008 Nov 10;26(32):5233-9. doi: 10.1200/JCO.2008.16.5449. Epub 2008 Sep 22.

42.

Non-patient related variables affecting levels of vascular endothelial growth factor in urine biospecimens.

Kirk MJ, Hayward RM, Sproull M, Scott T, Smith S, Cooley-Zgela T, Crouse NS, Citrin DE, Camphausen K.

J Cell Mol Med. 2008 Aug;12(4):1250-5. doi: 10.1111/j.1582-4934.2008.00182.x.

43.

Clinical biomarkers of angiogenesis inhibition.

Brown AP, Citrin DE, Camphausen KA.

Cancer Metastasis Rev. 2008 Sep;27(3):415-34. doi: 10.1007/s10555-008-9143-x. Review.

44.

Post-collection, pre-measurement variables affecting VEGF levels in urine biospecimens.

Hayward RM, Kirk MJ, Sproull M, Scott T, Smith S, Cooley-Zgela T, Crouse NS, Citrin DE, Camphausen K.

J Cell Mol Med. 2008 Jan-Feb;12(1):343-50. doi: 10.1111/j.1582-4934.2007.00135.x.

45.

Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?

Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, Restifo NP.

Nat Clin Pract Oncol. 2006 Dec;3(12):668-81. Review.

46.

Early observed transient prostate-specific antigen elevations on a pilot study of external beam radiation therapy and fractionated MRI guided high dose rate brachytherapy boost.

Singh AK, Guion P, Susil RC, Citrin DE, Ning H, Miller RW, Ullman K, Smith S, Crouse NS, Godette DJ, Stall BR, Coleman CN, Camphausen K, Ménard C.

Radiat Oncol. 2006 Aug 16;1:28.

Supplemental Content

Loading ...
Support Center